The global Eubiotics Market is on a steady growth path through 2035, as antibiotic growth promoter regulation and rising livestock production continue reshaping animal nutrition strategy worldwide. “According to a recent study by SNS Insider, the global Eubiotics Market size valued at USD 7.51 billion in 2025, is anticipated to grow to USD 16.27 billion by 2035, registering a CAGR of 8.17% over the 2026-2035 forecast period.”
Eubiotics has moved from a niche animal nutrition concept to a genuinely mainstream feed additive category over the past decade, and regulation, more than any single scientific breakthrough, is what made that shift happen. The EU's veterinary medicine rules and the U.S. FDA's antibiotic growth promoter guidance both compressed what might have otherwise been a slower, more gradual industry transition into something closer to a mandate.
Manufacturers are responding with real investment, consolidation among the largest players and continued product innovation across probiotics, prebiotics, and essential oils reflect just how much capital is flowing into positioning for continued growth in this category.
To Get Detailed Insights on the Eubiotics Market – Request a Sample Report
Essential Oils Emerge as a High-Growth Natural Alternative
Where probiotics built the eubiotics category's foundation, essential oils are increasingly capturing attention as a fully plant-derived alternative that resonates with both regulatory requirements and consumer-facing clean-label marketing.
This shift reflects a broader pattern across the eubiotics category, where natural sourcing credentials are becoming as important a purchasing consideration for producers as raw performance data.
Manufacturers investing in essential oil research and standardized extraction technology are positioning themselves to capture a disproportionate share of this fast-growing type category.
Key Market Findings Highlight High-Growth Segments
Probiotics held the largest share of the Eubiotics Market in 2025, at 42%, reflecting the deepest body of clinical and field research among all eubiotic types.
Essential oils are the fastest-growing type, expanding at a 9.85% CAGR, pulled forward by producers seeking natural antimicrobial alternatives with strong clean-label appeal.
By livestock, poultry led with 36.50% share in 2025, while aquaculture is growing fastest, at a 9.10% CAGR, propelled by shrimp and salmon farming intensification across Southeast Asia and Scandinavia.
Gut health applications remained the largest function category at 44% share, but immune support is climbing fastest, at a 9.60% CAGR, as producers recognize the gut microbiome's broader role in disease resistance.
Formulation Sophistication and Regulatory Compliance Anchor Competitive Positioning
Manufacturers are increasingly being evaluated on formulation sophistication and demonstrated performance data nearly as much as on price, particularly among larger livestock operations navigating antibiotic-free production requirements.
Investment in encapsulation technology and synbiotic formulations is becoming a genuine competitive differentiator among larger players, while suppliers without that investment increasingly compete only in commodity, price-sensitive segments.
This divide is expected to sharpen further as more markets adopt Europe-style antibiotic growth promoter restrictions.
Europe Leads as Middle East & Africa Grows Fastest
Europe holds the largest share of global market revenue, anchored by among the strictest antibiotic regulations in the world under Regulation 2019/6 on veterinary medicinal products. The Middle East & Africa region, meanwhile, is growing fastest, as livestock production intensifies and antibiotic-free farming practices gain traction alongside rising food safety expectations.
Asia Pacific holds a substantial and steadily expanding share as well, anchored by China's massive livestock production base and Japan's antibiotic-free livestock policies supporting premium meat export demand.
Leading Companies Drive Innovation and Competition
Competition in this market centers on formulation technology, species-specific product development, and regulatory compliance capability nearly as much as on price, with significant consolidation activity reshaping the competitive landscape among larger players.
Some of the major companies that operate in the global eubiotics market are Novonesis A/S, DSM-Firmenich AG, BASF SE, Cargill, Incorporated, Kemin Industries, Inc., Lallemand Inc., Novus International, Inc., BENEO GmbH.
An SNS Insider Analyst Santosh Bhul commented, “Eubiotics has earned its place as the credible, performance-validated alternative to antibiotic growth promoters, and the companies capturing the fastest-growing parts of this market are the ones combining rigorous clinical validation with genuine formulation innovation across probiotics, essential oils, and synbiotics. As antibiotic regulation keeps tightening globally, manufacturers with proven performance data and scalable production capacity are best positioned to lead.”
About the Author
Get in touch
